SYCP2 Antibody

What is SYCP2 and why is it important in research?

SYCP2 is a major component of the axial/lateral elements of synaptonemal complexes (SCs) during meiotic prophase. In humans, the canonical protein has 1530 amino acid residues with a molecular mass of 175.6 kDa and is primarily localized in the nucleus . SYCP2 is crucial for studying meiosis, as it plays an essential role in synaptonemal complex assembly and chromosomal synapsis. Recent research has also revealed its unexpected role in cancer, particularly in conferring resistance to DNA-damaging agents in breast and ovarian cancers . SYCP2's dual function in normal meiotic processes and pathological conditions makes it a significant research target across multiple fields.

What applications are SYCP2 antibodies commonly used for?

SYCP2 antibodies are primarily used in the following applications:

• Western Blotting (WB): The most common application, useful for detecting SYCP2 protein expression levels

• Immunofluorescence (IF): For visualizing SYCP2 localization along chromosomal axes

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative detection of SYCP2

• Immunohistochemistry (IHC): For detecting SYCP2 in tissue sections

These applications collectively enable researchers to study SYCP2's expression, localization, and interactions in various experimental contexts.

How are SYCP2 antibodies validated for research applications?

SYCP2 antibodies undergo multi-step validation processes to ensure specificity and sensitivity:

• Western blot analysis using positive control tissues (typically testis) to confirm the expected molecular weight (~190 kD)

• Immunostaining of spread nuclei of spermatocytes and double immunostaining with previously characterized anti-SYCP2 antibodies

• Testing across multiple cell lines (e.g., SKOV3, BT474, Jurkat, PC-3, U937, MCF7) to confirm consistent reactivity patterns

• Cross-reactivity testing against related proteins, particularly other synaptonemal complex proteins

• Validation across multiple applications (WB, IF, IHC) to ensure consistent performance

Researchers should review the validation data provided by manufacturers or in literature to select antibodies appropriate for their specific experimental needs.

How can I optimize SYCP2 antibody staining in meiotic chromosome spreads?

Optimizing SYCP2 antibody staining in meiotic chromosome spreads requires attention to several critical parameters:

• Fixation method: For meiotic spreads, paraformaldehyde (1-4%) is typically optimal for preserving SYCP2 epitopes while maintaining chromosome morphology.

• Blocking solution: Use 5-10% normal serum (from the species in which the secondary antibody was raised) with 0.1-0.3% Triton X-100 to reduce background.

• Antibody dilution: Start with manufacturer's recommended dilution (typically 1:500-1:2000 for WB applications ) and optimize through titration experiments.

• Co-staining considerations: When performing double-immunostaining with SYCP3 antibodies, selecting antibodies raised in different host species is crucial for avoiding cross-reactivity.

• Incubation conditions: Overnight incubation at 4°C typically yields optimal signal-to-noise ratio for SYCP2 staining.

• Signal amplification: For weak SYCP2 signals, consider tyramide signal amplification or highly sensitive detection systems.

Remember that SYCP2 localizes to axial chromosomal cores even in the absence of SYCP3, as demonstrated in SYCP2 mutant mice studies , which can serve as an important control for antibody specificity.

What are the key considerations when designing experiments to study SYCP2-SYCP3 interactions?

When investigating SYCP2-SYCP3 interactions, researchers should consider:

• Domain-specific antibodies: The C-terminal coiled-coil domain (residues 1379-1433 in mouse SYCP2) is critical for SYCP2-SYCP3 interaction . Using antibodies targeting different domains can provide insights into structural requirements.

• Co-immunoprecipitation protocols:

  • Use soluble nuclear fractions of testicular protein extracts

  • Include appropriate controls (e.g., IgG control)

  • Consider reciprocal IPs with both anti-SYCP2 and anti-SYCP3 antibodies

• GST pulldown assays: These can verify direct interaction in vitro, as demonstrated in previous studies .

• Mutant models: Studies with truncated SYCP2 proteins lacking the coiled-coil domain (SYCP2t) have shown that this domain is necessary for binding to SYCP3 in vivo .

• Proximity ligation assays: These can detect protein-protein interactions in situ with high sensitivity.

• Visualization techniques: Double-immunostaining with anti-SYCP2 and anti-SYCP3 antibodies can reveal co-localization patterns along chromosomal axes.

The research by Yang et al. (2006) provides a comprehensive methodological framework for studying these interactions .

How can I use SYCP2 antibodies to investigate DNA repair mechanisms in cancer cells?

Recent research has identified SYCP2's role in conferring resistance to DNA-damaging agents in cancer cells through R-loop-mediated DNA double-strand break (DSB) repair . To investigate this:

• Experimental design considerations:

  • Compare SYCP2-expressing vs. SYCP2-knockdown/knockout cancer cell lines

  • Assess response to various DNA-damaging agents (PARP inhibitors, topoisomerase I inhibitors, platinum compounds)

  • Measure DSB repair efficiency through γH2AX foci resolution kinetics

• Critical assays:

  • R-loop detection using S9.6 antibody (against RNA:DNA hybrids)

  • RAD51 foci formation assessment (SYCP2 promotes RAD51 recruitment independently of BRCA1)

  • Transcription-coupled homologous recombination (TC-HR) assays

  • Sensitivity assays to various DNA-damaging agents

• Immunofluorescence co-localization studies:

  • SYCP2 with R-loops

  • SYCP2 with RAD51

  • SYCP2 with γH2AX

• Clinical correlation analyses:

  • SYCP2 expression levels in patient samples

  • Correlation with treatment response to DDR-targeting therapies

These approaches can help delineate SYCP2's role in DNA repair and potentially identify therapeutic vulnerabilities in SYCP2-overexpressing cancers .

What are common issues when using SYCP2 antibodies in Western blot and how can they be resolved?

For optimal results, remember SYCP2 has an apparent molecular mass of 190 kD in Western blot analysis despite its calculated weight of 175.6 kDa , likely due to post-translational modifications.

How can I troubleshoot weak or absent SYCP2 immunofluorescence signals in meiotic chromosome preparations?

When troubleshooting weak or absent SYCP2 immunofluorescence signals:

• Sample preparation issues:

  • Ensure proper fixation (1-4% paraformaldehyde is recommended)

  • Optimize permeabilization conditions (0.1-0.5% Triton X-100)

  • Check that samples are from appropriate developmental stage (SYCP2 expression is stage-specific)

• Antibody-related factors:

  • Verify antibody recognizes the appropriate species (human, mouse, rat)

  • Confirm antibody epitope accessibility (some epitopes may be masked in certain conformations)

  • Test different antibody concentrations (serial dilutions from 1:100 to 1:1000)

  • Consider using antibodies targeting different SYCP2 regions

• Technical considerations:

  • Extend primary antibody incubation time (overnight at 4°C)

  • Try signal amplification methods (TSA, brighter fluorophores)

  • Optimize mounting media (anti-fade reagents improve signal retention)

  • Adjust microscope settings (exposure time, gain)

• Biological variables:

  • Remember that SYCP2 distribution changes throughout meiotic prophase

  • In abnormal meiosis, SYCP2 patterns may be disrupted

  • In certain genetic backgrounds (e.g., SYCP3 mutants), SYCP2 localization may be altered

Using appropriate positive controls (normal spermatocytes) and negative controls (pre-meiotic cells) is essential for accurate interpretation.

What considerations are important when using SYCP2 antibodies in cancer research applications?

When applying SYCP2 antibodies in cancer research:

• Expression variability:

  • SYCP2 is aberrantly expressed in breast and ovarian cancers but expression levels vary significantly between samples

  • Validate antibody performance in your specific cancer model

  • Consider quantitative methods (WB, ELISA) alongside qualitative (IHC, IF)

• Technical adaptations:

  • For formalin-fixed paraffin-embedded (FFPE) cancer tissues, antigen retrieval optimization is critical

  • Cell line studies may require different fixation protocols than clinical samples

  • Background can be higher in certain cancer tissues; optimize blocking conditions

• Interpretation challenges:

  • Distinguish between specific SYCP2 signal and non-specific binding

  • Nuclear localization should be confirmed for true SYCP2 positivity

  • Consider dual staining with other DDR markers for functional studies

• Control selection:

  • Include known SYCP2-positive tissues (testis) as positive controls

  • Use SYCP2-negative cell lines or SYCP2-knockdown samples as negative controls

  • Consider isotype controls to assess non-specific binding

• Functional correlation:

  • Pair SYCP2 detection with functional assays for DNA repair

  • Correlate with clinical outcomes or treatment response data

  • Consider co-staining with R-loop markers to investigate mechanistic relationships

These considerations will help ensure reliable and interpretable results when using SYCP2 antibodies in cancer research applications.

How does SYCP2's role in meiosis differ from its function in cancer cells?

SYCP2's functions in meiosis versus cancer cells represent a fascinating example of protein repurposing:

This dual functionality makes SYCP2 both an important marker for understanding fundamental meiotic processes and a potential therapeutic target or predictive biomarker in cancer treatment .

What experimental approaches can determine the specificity of SYCP2 antibodies?

To rigorously determine SYCP2 antibody specificity:

• Genetic validation approaches:

  • Testing in SYCP2 knockout/knockdown models

  • Comparison with SYCP2 mutant models (e.g., those lacking specific domains)

  • Analysis in cells with CRISPR-mediated SYCP2 deletion

• Biochemical validation methods:

  • Western blot showing single band at expected molecular weight (~190 kD)

  • Peptide competition assays using the immunizing peptide

  • Immunodepletion experiments

• Cross-platform consistency:

  • Concordant results across multiple detection methods (WB, IF, IHC)

  • Consistent localization patterns in different preparations

  • Reproducible results with antibodies targeting different SYCP2 epitopes

• Biological validation:

  • Expected expression pattern (high in testis, aberrant in certain cancers)

  • Correct subcellular localization (nuclear)

  • Appropriate developmental timing of expression

• Technical controls:

  • Primary antibody omission

  • Isotype controls

  • Comparison with commercially validated SYCP2 antibodies

Rigorous specificity validation ensures reliable experimental outcomes and interpretable results across different research applications.

How can researchers use SYCP2 antibodies to investigate fertility disorders?

SYCP2 antibodies are valuable tools for investigating fertility disorders, particularly male infertility:

• Diagnostic applications:

  • Analysis of testicular biopsies from infertile men to assess SYCP2 expression and localization

  • Evaluation of meiotic progression through SYCP2 staining patterns

  • Identification of potential SYCP2 mutations or expression abnormalities

• Mechanistic investigations:

  • Study of SYCP2-SYCP3 interactions in patient samples

  • Assessment of synaptonemal complex formation and integrity

  • Characterization of chromosomal synapsis defects

• Experimental approaches:

  • Immunofluorescence on testicular sections or spread spermatocytes

  • Western blot analysis of SYCP2 expression levels

  • Co-immunoprecipitation to assess protein-protein interactions

• Clinical-research correlations:

  • Compare SYCP2 patterns between fertile controls and infertile patients

  • Correlate SYCP2 abnormalities with specific infertility phenotypes

  • Link genetic variants in SYCP2 with protein function

Research has established that SYCP2 deficiency causes male sterility due to meiotic arrest while females experience reduced fertility . The SYCP2 gene has been associated with spermatogenic failure , making it a relevant target for infertility research.

How can researchers use SYCP2 antibodies to predict cancer treatment response?

Recent research indicates SYCP2 expression correlates with resistance to DNA-damaging therapies, offering potential predictive applications:

• Clinical correlation studies:

  • IHC analysis of SYCP2 in tumor samples before treatment

  • Correlation with response to:

    • PARP inhibitors

    • Topoisomerase I inhibitors

    • Platinum-based therapies

• Experimental validation approaches:

  • In vitro drug sensitivity assays comparing SYCP2-high vs. SYCP2-low cancer cells

  • Patient-derived xenograft models to validate predictive power

  • Retrospective analysis of clinical cohorts

• Combination strategies:

  • Assessment of SYCP2 alongside other DDR markers

  • Development of predictive algorithms incorporating multiple markers

  • Testing SYCP2 inhibition as a sensitization strategy

• Methodology considerations:

  • Standardization of SYCP2 detection and quantification methods

  • Determination of clinically relevant SYCP2 expression thresholds

  • Validation across multiple cancer types

Studies of clinical cohorts have found that SYCP2 overexpression correlates with breast cancer resistance to antibody-conjugated TOP1 inhibitors and ovarian cancer resistance to platinum treatment , suggesting significant potential for SYCP2 as a predictive biomarker.

What are the challenges in developing and validating SYCP2 function-blocking antibodies?

Developing function-blocking antibodies against SYCP2 presents several challenges:

• Target domain identification:

  • The coiled-coil domain (residues 1379-1433 in mouse) is critical for SYCP3 interaction

  • In cancer cells, domains involved in R-loop formation and RAD51 recruitment would be targets

  • Epitope mapping is essential to identify functional domains

• Antibody design considerations:

  • Format selection (full IgG vs. Fab fragments vs. single-domain antibodies)

  • Species cross-reactivity requirements

  • Cell penetration capabilities for intracellular targeting

• Validation challenges:

  • Demonstrating target engagement inside cells

  • Confirming disruption of specific protein-protein interactions

  • Distinguishing between protein depletion and functional inhibition

• Experimental validation strategies:

  • In vitro interaction disruption assays

  • Cellular phenotype rescue experiments

  • Comparison with genetic knockdown/knockout models

• Application-specific considerations:

  • For cancer applications: demonstrating sensitization to DNA-damaging agents

  • For fertility research: confirming effects on synaptonemal complex formation

Function-blocking antibodies could have significant research value and potential therapeutic applications in SYCP2-overexpressing cancers, though development complexity is high.

How should researchers interpret conflicting SYCP2 antibody results across different experimental systems?

When facing conflicting SYCP2 antibody results:

• Technical variables assessment:

  • Antibody characteristics:

    • Different epitopes recognized

    • Polyclonal vs. monoclonal nature

    • Host species differences

  • Experimental conditions:

    • Fixation/preparation methods

    • Detection systems

    • Antibody concentrations

• Biological variables consideration:

  • Species differences (human SYCP2 shares 63% identity with mouse, 88% with rat)

  • Tissue-specific post-translational modifications

  • Expression of alternative isoforms

  • Context-dependent protein interactions

• Systematic troubleshooting approach:

  • Control experiments with known positive/negative samples

  • Side-by-side comparison of antibodies under identical conditions

  • Independent verification with orthogonal methods (e.g., mass spectrometry)

  • Genetic validation (siRNA, CRISPR) to confirm specificity

• Interpretation framework:

  • Consider biological context (meiotic cells vs. cancer cells)

  • Recognize that both results may be correct in different contexts

  • Evaluate consistency with known SYCP2 biology

  • Assess technical limitations of each method

Conflicting results may reflect genuine biological differences rather than technical artifacts, particularly given SYCP2's distinct roles in meiosis versus cancer contexts .